FDA Greenlights Groundbreaking ALZN002 Vaccine Trial: Alzamend Neuro Taking Step Closer to Treating Mild to Moderate Alzheimer’s Dementia

Alzamend Neuro, Inc., is pleased to announce that the US Food and Drug Administration has given the green light for its Phase I/IIA Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type.

The FDA has issued a “Study May Proceed” letter, allowing Alzamend Neuro to move forward with its research and development of ALZN002.

Alzamend Neuro, Inc. made an unfortunate mistake when they mistakenly issued a release.

On April 3, 2023, at 08:50 AM Eastern Time, a new release was issued to replace the existing one. Get ready for the exciting update!

Leave a Comment